October 2022

Contents

Editorial

• HTB October 2022 (3 October 2022)

Special reports

• Monkeypox into Autumn: still no emergency funding, vaccine efficacy and UK declines further vaccines

Conference reports

• 14th International Workshop on HIV & Pediatrics

• First paediatric pharmacokinetic data of dolutegravir in combination with a TAF-based NRTI backbone

• 24th International AIDS Conference (AIDS 2022): further reports

• AIDS 2022: Efficacy of DTG- vs EFV-based first-line ART in advanced HIV with CD4 <50 cells/mm3

• AIDS 2022: Gender-affirming hormones, weight gain and ART

Antiretrovirals

• Islatravir update: treatment studies to use a lower dose but PrEP research discontinued in favour of MK-8537

• Low levels of RPV-LA might explain failure with injectable ART despite perfect adherence

mpox (monkeypox)

• Tecovirimat treatment for monkeypox in the UK: importance of the PLATINUM study

• Levels of monkeypox viral load in different body sites supports highest risk from body contact

• Severe complication of monkeypox reported to the US CDC: risks associated with HIV and other causes of immunosuppression

• New reports on MPX vaccine efficacy suggest protection but cases reported after two shots

• Other monkeypox studies of interest

• BHIVA, BASHH and other professional organisations publish open letters on the refusal by the UK government to acknowledge monkeypox crisis

Coinfections and complications

• Reduced HAND prevalence in large cross-sectional cohort study  

Resistance

• Update to IAS-USA drug resistance tables

Research studies

• Switch study for people with insomnia using dolutegravir: still enrolling

Future meetings

• BHIVA General Medicine Course 2022

PDFs

• HTB: no. 10 (3 October 2022) PDF download